Pegavision Corp
TWSE:6491
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
367
532
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pegavision Corp
Cash & Cash Equivalents
Pegavision Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pegavision Corp
TWSE:6491
|
Cash & Cash Equivalents
NT$1.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medtecs International Corporation Ltd
SGX:546
|
Cash & Cash Equivalents
$17.6m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
58%
|
CAGR 10-Years
22%
|
|
|
V
|
Visco Vision Inc
TWSE:6782
|
Cash & Cash Equivalents
NT$520.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
SciVision Biotech Inc
TWSE:1786
|
Cash & Cash Equivalents
NT$568.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
OK Biotech Co Ltd
TWSE:4155
|
Cash & Cash Equivalents
NT$360.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Pegavision Corp
Glance View
Pegavision Corp. focusing on research, development, manufacture and marketing of soft contact lenses and the medical optic devices. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2014-12-30. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Pegavision Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B
TWD
Based on the financial report for Jun 30, 2024, Pegavision Corp's Cash & Cash Equivalents amounts to 1.1B TWD.
What is Pegavision Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
22%
Over the last year, the Cash & Cash Equivalents growth was 3%. The average annual Cash & Cash Equivalents growth rates for Pegavision Corp have been -15% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
